Skip to main content
NCBI home page
The British Journal of Cancer. Supplement logoLink to The British Journal of Cancer. Supplement
. 1992 Aug;18:S36–S40.

Cisplatin therapy in infants: short and long-term morbidity.

P R Brock 1, E C Yeomans 1, S C Bellman 1, J Pritchard 1
PMCID: PMC2149657  PMID: 1323992

Abstract

The tolerance to and toxicity of cisplatin treatment was retrospectively studied in 30 infants. A total of 191 courses were given with a median of six per child and a median cumulative dose of 400 mg m-2. Electrolyte disturbances were noted in 15/23 infants (38:144 courses): hypomagnesaemia, which was dose related, in 10/23 (25/144 courses), hyponatraemia in 6/23 (7:144 courses), hypercalcaemia in 4/23 (6/144 courses), and hypocalcaemia in 3/23 (4/144 courses). Seizures occurred in two infants. Vomiting followed 31/191 courses and neutropenic febrile episodes 23/191 courses. Median survival is 6 years 1 month. Six children have died of progressive malignancy. Glomerular filtration rate was less than 80 ml min-1 per 1.73 m2 in 15/29 children, at or within a month of the end of treatment; of ten retested at follow-up, eight had increased to more than 80 ml min-1 per 1.73 m2 (P = 0.027). High-frequency hearing loss was observed in 10/28 children, but was only significant in five (four grade 2 and one grade 3). In conclusion: the long-term toxicity of cisplatin in infants, at this dose range and schedule, is no more severe than in older children.

Full text

PDF
S36

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aperia A., Broberger O., Thodenius K., Zetterström R. Development of renal control of salt and fluid homeostasis during the first year of life. Acta Paediatr Scand. 1975 May;64(3):393–398. doi: 10.1111/j.1651-2227.1975.tb03853.x. [DOI] [PubMed] [Google Scholar]
  2. Bianchetti M. G., Kanaka C., Ridolfi-Lüthy A., Wagner H. P., Hirt A., Paunier L., Peheim E., Oetliker O. H. Chronic renal magnesium loss, hypocalciuria and mild hypokalaemic metabolic alkalosis after cisplatin. Pediatr Nephrol. 1990 May;4(3):219–222. doi: 10.1007/BF00857658. [DOI] [PubMed] [Google Scholar]
  3. Brock P. R., Bellman S. C., Yeomans E. C., Pinkerton C. R., Pritchard J. Cisplatin ototoxicity in children: a practical grading system. Med Pediatr Oncol. 1991;19(4):295–300. doi: 10.1002/mpo.2950190415. [DOI] [PubMed] [Google Scholar]
  4. Brock P. R., Koliouskas D. E., Barratt T. M., Yeomans E., Pritchard J. Partial reversibility of cisplatin nephrotoxicity in children. J Pediatr. 1991 Apr;118(4 Pt 1):531–534. doi: 10.1016/s0022-3476(05)83372-4. [DOI] [PubMed] [Google Scholar]
  5. Brock P., Pritchard J., Bellman S., Pinkerton C. R. Ototoxicity of high-dose cis-platinum in children. Med Pediatr Oncol. 1988;16(5):368–369. doi: 10.1002/mpo.2950160517. [DOI] [PubMed] [Google Scholar]
  6. Chantler C., Barratt T. M. Estimation of glomerular filtration rate from plasma clearance of 51-chromium edetic acid. Arch Dis Child. 1972 Aug;47(254):613–617. doi: 10.1136/adc.47.254.613. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Chantler C., Garnett E. S., Parsons V., Veall N. Glomerular filtration rate measurement in man by the single injection methods using 51Cr-EDTA. Clin Sci. 1969 Aug;37(1):169–180. [PubMed] [Google Scholar]
  8. Douglass E. C., Green A. A., Wrenn E., Champion J., Shipp M., Pratt C. B. Effective cisplatin (DDP) based chemotherapy in the treatment of hepatoblastoma. Med Pediatr Oncol. 1985;13(4):187–190. doi: 10.1002/mpo.2950130405. [DOI] [PubMed] [Google Scholar]
  9. Einhorn L. H., Donohue J. Cis-diamminedichloroplatinum, vinblastine, and bleomycin combination chemotherapy in disseminated testicular cancer. Ann Intern Med. 1977 Sep;87(3):293–298. doi: 10.7326/0003-4819-87-3-293. [DOI] [PubMed] [Google Scholar]
  10. Hamilton C. R., Bliss J. M., Horwich A. The late effects of cis-platinum on renal function. Eur J Cancer Clin Oncol. 1989 Feb;25(2):185–189. doi: 10.1016/0277-5379(89)90006-0. [DOI] [PubMed] [Google Scholar]
  11. Hansen S. W., Groth S., Daugaard G., Rossing N., Rørth M. Long-term effects on renal function and blood pressure of treatment with cisplatin, vinblastine, and bleomycin in patients with germ cell cancer. J Clin Oncol. 1988 Nov;6(11):1728–1731. doi: 10.1200/JCO.1988.6.11.1728. [DOI] [PubMed] [Google Scholar]
  12. Hayes F. A., Green A. A., Casper J., Cornet J., Evans W. E. Clinical evaluation of sequentially scheduled cisplatin and VM26 in neuroblastoma: response and toxicity. Cancer. 1981 Oct 15;48(8):1715–1718. doi: 10.1002/1097-0142(19811015)48:8<1715::aid-cncr2820480805>3.0.co;2-y. [DOI] [PubMed] [Google Scholar]
  13. Jaffe N., Keifer R., 3rd, Robertson R., Cangir A., Wang A. Renal toxicity with cumulative doses of cis-diamminedichloroplatinum-II in pediatric patients with osteosarcoma. Effect on creatinine clearance and methotrexate excretion. Cancer. 1987 May 1;59(9):1577–1581. doi: 10.1002/1097-0142(19870501)59:9<1577::aid-cncr2820590908>3.0.co;2-p. [DOI] [PubMed] [Google Scholar]
  14. Pinkerton C. R., Lewis I. J., Pearson A. D., Stevens M. C., Barnes J. Carboplatin or cisplatin? Lancet. 1989 Jul 15;2(8655):161–161. doi: 10.1016/s0140-6736(89)90217-1. [DOI] [PubMed] [Google Scholar]
  15. Shafford E. A., Rogers D. W., Pritchard J. Advanced neuroblastoma: improved response rate using a multiagent regimen (OPEC) including sequential cisplatin and VM-26. J Clin Oncol. 1984 Jul;2(7):742–747. doi: 10.1200/JCO.1984.2.7.742. [DOI] [PubMed] [Google Scholar]
  16. Simmons F. B. Identification of hearing loss in infants and young children. Otolaryngol Clin North Am. 1978 Feb;11(1):19–28. [PubMed] [Google Scholar]
  17. Sohmer H., Kinarti R. Survey of attempts to use auditory evoked potentials to obtain an audiogram. Review article. Br J Audiol. 1984 Nov;18(4):237–244. doi: 10.3109/03005368409078954. [DOI] [PubMed] [Google Scholar]
  18. Womer R. B., Pritchard J., Barratt T. M. Renal toxicity of cisplatin in children. J Pediatr. 1985 Apr;106(4):659–663. doi: 10.1016/s0022-3476(85)80098-6. [DOI] [PubMed] [Google Scholar]

Articles from The British Journal of Cancer. Supplement are provided here courtesy of Cancer Research UK

RESOURCES